<div id="readability-page-1"><div><p>Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.</p><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Insider Ownership</strong></td><td><strong>Earnings Growth</strong></td></tr><tr><td>Uxin (UXIN)</td><td>35.6%</td><td>74.1%</td></tr><tr><td>Upstart Holdings (UPST)</td><td>13%</td><td>52.6%</td></tr><tr><td>Precigen (PGEN)</td><td>11.9%</td><td>68.4%</td></tr><tr><td>Karman Holdings (KRMN)</td><td>17%</td><td>53.2%</td></tr><tr><td>GBank Financial Holdings (GBFH)</td><td>27.3%</td><td>42.2%</td></tr><tr><td>Enovix (ENVX)</td><td>11.4%</td><td>41.1%</td></tr><tr><td>Clene (CLNN)</td><td>13.2%</td><td>62.2%</td></tr><tr><td>Better Home &amp; Finance Holding (BETR)</td><td>20.7%</td><td>97.4%</td></tr><tr><td>Astera Labs (ALAB)</td><td>10.3%</td><td>29.0%</td></tr><tr><td>AppLovin (APP)</td><td>27.3%</td><td>21.6%</td></tr></tbody></table></div><p>Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p><p>Let's explore several standout options from the results in the screener.</p><h2>ASP Isotopes (ASPI)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> ASP Isotopes Inc. is a development stage advanced materials company focused on producing, distributing, marketing, and selling isotopes with a market cap of $564.05 million.</p><p><strong>Operations:</strong> The company generates revenue from two main segments: Construction Services, which accounts for $18.18 million, and Specialist Isotopes and Related Services, contributing $5.67 million.</p><p><strong>Insider Ownership:</strong> 13.5%</p><p><strong>Revenue Growth Forecast:</strong> 49.4% p.a.</p><p>ASP Isotopes is experiencing substantial revenue growth, with a forecast of 49.4% annually, surpassing the US market average. Despite past shareholder dilution and a volatile share price, the company is on track to become profitable in three years. Recent developments include advancements in its Renergen Helium Project and strategic partnerships for nuclear fuel production. However, challenges remain with delayed SEC filings and significant net losses reported for 2025 at US$175.09 million against revenues of US$23.85 million.</p><ul><li>Take a closer look at ASP Isotopes' potential here in our earnings growth report.</li><li>The analysis detailed in our ASP Isotopes valuation report hints at an inflated share price compared to its estimated value.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8686b2df-74f7-4596-899d-4091f07eee9a/chart/earnings-and-revenue-growth"/><figcaption>ASPI Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>Eton Pharmaceuticals (ETON)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes treatments for rare diseases, with a market cap of $719.22 million.</p><p><strong>Operations:</strong> The company's revenue is primarily derived from its segment focused on developing and commercializing prescription drug products, which generated $79.95 million.</p><p><strong>Insider Ownership:</strong> 15%</p><p><strong>Revenue Growth Forecast:</strong> 29.8% p.a.</p><p>Eton Pharmaceuticals is poised for significant growth, with revenue expected to increase by 29.8% annually, outpacing the US market average. Recent FDA approval of DESMODA and the acquisition of HEMANGEOL commercialization rights bolster its product portfolio. The company anticipates 2026 revenues exceeding US$110 million, supported by strategic in-licensing deals and a focus on ultra-rare diseases. Despite a net loss of US$4.6 million in 2025, Eton aims for profitability within three years.</p><ul><li>Navigate through the intricacies of Eton Pharmaceuticals with our comprehensive analyst estimates report here.</li><li>Our valuation report unveils the possibility Eton Pharmaceuticals' shares may be trading at a premium.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/138d2dd4-ea25-478d-b12d-9bef35fe2f81/chart/earnings-and-revenue-growth"/><figcaption>ETON Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>FirstSun Capital Bancorp (FSUN)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> FirstSun Capital Bancorp, with a market cap of $1.05 billion, operates as the bank holding company for Sunflower Bank, National Association, offering commercial and consumer banking and financial services to small and medium-sized companies in the United States.</p><p><strong>Operations:</strong> The company's revenue is primarily derived from its Banking segment, which accounts for $322.60 million, supplemented by $76.56 million from Mortgage Operations, while the Corporate segment reflects a loss of $4.49 million.</p><p><strong>Insider Ownership:</strong> 37.1%</p><p><strong>Revenue Growth Forecast:</strong> 31.9% p.a.</p><p>FirstSun Capital Bancorp is experiencing robust growth, with earnings projected to rise 43.6% annually, surpassing the US market average. The company trades at a significant discount to its estimated fair value and offers good relative value compared to peers. Recent board changes include the addition of key directors from First Foundation Inc., enhancing governance post-merger. Despite being dropped from several indices, FirstSun's insider buying remains positive, indicating confidence in its growth trajectory.</p><ul><li>Delve into the full analysis future growth report here for a deeper understanding of FirstSun Capital Bancorp.</li><li>Our valuation report unveils the possibility FirstSun Capital Bancorp's shares may be trading at a discount.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1348cc44-c00a-4259-bc99-9e48d6623403/chart/earnings-and-revenue-growth"/><figcaption>FSUN Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>Seize The Opportunity</h2><ul><li>Dive into all 203 of the Fast Growing US Companies With High Insider Ownership we have identified here.</li><li>Want To Explore Some Alternatives? We've found 11 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.      It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.      All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

UXIN

ETON

FSUN

<p>The U.S. market has risen 3.1% in the past week and 27% over the last year, with earnings expected to grow by 16% annually. Growth companies with high insider ownership are highlighted as attractive investments. Top companies include Uxin (35.6% insider ownership, 74.1% earnings growth) and Eton Pharmaceuticals (15% insider ownership, 29.8% earnings growth). ASP Isotopes and FirstSun Capital Bancorp also show strong growth potential. The article emphasizes the importance of insider ownership as a confidence indicator and provides insights into various companies' financial forecasts and market positions.</p>

April 2026's Top Growth Companies With Strong Insider Ownership